Iressa Lung Cancer Drug Eyed As Worthy Candidate For Companion Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Early collaborations between drug and diagnostic firms frequently yield favorable FDA review of pharmaceutical data, speakers attested at SMI's Opportunities & Technology Trends in Global Diagnostic Testing Markets conference in London June 28-29
You may also be interested in...
Genzyme Licenses Biomarker To Develop Lung Cancer Companion Diagnostic
Genzyme's development of a lung cancer drug companion diagnostic would represent the firm's first in-house oncological test offering
Genzyme Licenses Biomarker To Develop Lung Cancer Companion Diagnostic
Genzyme's development of a lung cancer drug companion diagnostic would represent the firm's first in-house oncological test offering
Dako HercepTest To Launch Oct. 27 In Conjunction With Genentech Herceptin
Market release of the Dako HercepTest will commence Oct. 27, the company said, following FDA premarket approval of the immunohistochemical anti-HER2 assay on Sept. 25.